{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:01:55Z","timestamp":1791925315148,"version":"4.3.4"},"reference-count":65,"publisher":"The Korean Academy of Tuberculosis and Respiratory Diseases","issue":"2","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015690","name":"Universitas Padjadjaran","doi-asserted-by":"crossref","award":["1595\/UN6.3.1\/PT.00\/2021"],"award-info":[{"award-number":["1595\/UN6.3.1\/PT.00\/2021"]}],"id":[{"id":"10.13039\/501100015690","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100015690","name":"Universitas Padjadjaran","doi-asserted-by":"crossref","award":["3855\/UN.C\/LT\/2019"],"award-info":[{"award-number":["3855\/UN.C\/LT\/2019"]}],"id":[{"id":"10.13039\/501100015690","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["e-trd.org"],"crossmark-restriction":true},"short-container-title":["Tuberc Respir Dis"],"published-print":{"date-parts":[[2022,4,1]]},"abstract":"<jats:p>Multidrug-resistant tuberculosis (MDR-TB) is caused by an organism that is resistant to both rifampicin and isoniazid. Extensively drug-resistant TB, a rare type of MDR-TB, is caused by an organism that is resistant to quinolone and one of group A TB drugs (i.e., linezolid and bedaquiline). In 2018, the World Health Organization revised the groupings of TB medicines and reclassified linezolid as a group A drug for the treatment of MDR-TB. Linezolid is a synthetic antimicrobial agent in the oxazolidinone class. Although linezolid has a good efficacy, it can cause substantial adverse events, especially hematologic toxicity. In both TB infection and linezolid mechanism of action, mitochondrial dysfunction plays an important role. In this concise review, characteristics of linezolid as an anti-TB drug are summarized, including its efficacy, pathogenesis of hematologic toxicity highlighting mitochondrial dysfunction, and the monitoring and management of hematologic toxicity.<\/jats:p>","DOI":"10.4046\/trd.2021.0122","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T02:47:48Z","timestamp":1642646868000},"page":"111-121","update-policy":"https:\/\/doi.org\/10.4046\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Concise Clinical Review of Hematologic Toxicity of Linezolid in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Role of Mitochondria"],"prefix":"10.4046","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7853-2221","authenticated-orcid":true,"given":"Amaylia","family":"Oehadian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prayudi","family":"Santoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4995-5054","authenticated-orcid":true,"given":"Rovina","family":"Ruslami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2481","reference":[{"key":"ref1","first-page":"7","volume-title":"Global tuberculosis report 2019","author":"Annabel","year":"2019"},{"key":"ref2","volume-title":"Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis [Internet]","year":"2020"},{"key":"ref3","volume-title":"Global tuberculosis report 2020: executive summary [Internet]","year":"2020"},{"key":"ref4","volume-title":"Rapid communication: key changes to treatment of multidrug-and rifampicin-resistant tuberculosis (MDR\/RR-TB) [Internet]","year":"2018"},{"key":"ref5","volume-title":"WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment: online annexes [Internet]","year":"2020"},{"key":"ref6","first-page":"e93","volume-title":"Treatment of drug-resistant tuberculosis. An official ATS\/CDC\/ERS\/IDSA clinical practice guideline","author":"Nahid","year":"2019"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2013.10.003"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00022912"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.1100169"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/nejm200511243532123"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01190-06"},{"key":"ref12","first-page":"347","volume-title":"Synthesis and characterization of degradation impurities of an antibiotic drug: linezolid","author":"Gudisela","year":"2018"},{"key":"ref13","first-page":"23","volume-title":"Linezolid: a new option for treating gram-positive infections","author":"Batts","year":"2000"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s164515"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr072"},{"key":"ref16","first-page":"603","volume-title":"Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drugresistant tuberculosis","author":"Zhang","year":"2015"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.11.0451"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-016-0156-y"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.18.0822"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00120-13"},{"key":"ref21","first-page":"821","volume-title":"Treatment correlates of successful outcomes in pulmonary multidrugresistant tuberculosis: an individual patient data meta-analysis","author":"Ahmad","year":"2018"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1201964"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00035114"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3083.2003.01318.x"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmyco.2016.06.001"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2009.05.009"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-015-1115-3"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2015.06.003"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.6.3707"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2011.3"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1086\/430441"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00542-17"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1056\/nejm200301023480123"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1c361"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1086\/340982"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1086\/422147"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh405"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.11.1010.34517"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01599-17"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/s0891-5520(03)00065-5"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1128\/aac.46.8.2723-2726.2002"},{"key":"ref42","first-page":"1846","volume-title":"Linezolid-induced thrombocytopenia is caused by suppression of platelet production via phosphorylation of myosin light chain 2","author":"Tajima","year":"2016"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13262"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1086\/338403"},{"key":"ref45","first-page":"2172","volume-title":"Toxicity assessment of Linezolid and the beneficial effects of human erythropoietin in mice","author":"Patel","year":"2012"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1177\/0300060518800126"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1086\/345744"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.10.017"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-010-0182-1"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks078"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/535616"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1901814"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh409"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki202"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-017-2960-5"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.3855\/jidc.10859"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2012.07.002"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2016.05.003"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-014-0674-5"},{"key":"ref60","volume-title":"Drug-resistant tuberculosis: a survival guide for clinicians [Internet]","year":"2016"},{"key":"ref61","volume-title":"The PIH guide to the medical management of multidrug-resistant tuberculosis [Internet]","year":"2014"},{"key":"ref62","volume-title":"Clinical and programmatic guide for patient management with new TB drugs, version 4.0 [Internet]","year":"2018"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2013.02.020"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy625"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00580-2019"}],"container-title":["Tuberculosis and Respiratory Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-trd.org\/upload\/pdf\/trd-2021-0122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-trd.org\/journal\/view.php?doi=10.4046\/trd.2021.0122","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-trd.org\/upload\/pdf\/trd-2021-0122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T01:44:47Z","timestamp":1649123087000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-trd.org\/journal\/view.php?doi=10.4046\/trd.2021.0122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"URL":"https:\/\/doi.org\/10.4046\/trd.2021.0122","relation":{},"ISSN":["1738-3536","2005-6184"],"issn-type":[{"value":"1738-3536","type":"print"},{"value":"2005-6184","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]},"assertion":[{"value":"2021-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-20","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-01","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}